Clinical Diabetes: A Publication of the American Diabetes Association, 41 (3), 467473
Safety considerations patients should know The FDA has warned about multiple risks tied to compound semaglutide sold for weight loss, including products labeled with nonexistent pharmacies, dosing mistakes from multi-dose vials, and formulations made with semaglutide salts (e.g., acetate or sodium) rather than the approved basedifferences that may affect safety and legality
10.1016/j.cmet.2007.08.003 254 ShimizuA.KairaK.KatoM.YasudaM.TakahashiA.TominagaH.et al
Blood work to measure serum magnesium is not routinely necessary unless you have kidney disease or are on multiple medications
Adipocyte research models: Evaluation of fat cell biology and related metabolic processes
Novo Nordisk, the maker of Ozempic and Wegovy, told CBS News that the drugs "are a well-established class of medicines, which have demonstrated long-term safety in clinical trials